Switch theme
Sign up to access all valuation multiples
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.
2014
n/a
Last FY Revenue $8.3M
Last FY EBITDA -$17.6M
$660M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, D&D Pharmatech achieved revenue of $8.3M and an EBITDA of -$17.6M.
D&D Pharmatech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See D&D Pharmatech valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $8.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.3M | XXX | XXX | XXX |
| Gross Margin | XXX | 100% | XXX | XXX | XXX |
| EBITDA | XXX | -$17.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -212% | XXX | XXX | XXX |
| EBIT | XXX | -$18.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -219% | XXX | XXX | XXX |
| Net Profit | XXX | -$20.8M | XXX | XXX | XXX |
| Net Margin | XXX | -250% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, D&D Pharmatech's stock price is KRW 86500 (or $63).
D&D Pharmatech has current market cap of KRW 926B (or $673M), and EV of KRW 909B (or $660M).
See D&D Pharmatech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $660M | $673M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, D&D Pharmatech has market cap of $673M and EV of $660M.
D&D Pharmatech's trades at 79.4x EV/Revenue multiple, and -37.5x EV/EBITDA.
Equity research analysts estimate D&D Pharmatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
D&D Pharmatech's P/E ratio is not available.
See valuation multiples for D&D Pharmatech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $673M | XXX | $673M | XXX | XXX | XXX |
| EV (current) | $660M | XXX | $660M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 79.4x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -37.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -36.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -32.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -40.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialD&D Pharmatech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
D&D Pharmatech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
D&D Pharmatech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for D&D Pharmatech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -212% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 204% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
D&D Pharmatech acquired XXX companies to date.
Last acquisition by D&D Pharmatech was XXXXXXXX, XXXXX XXXXX XXXXXX . D&D Pharmatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was D&D Pharmatech founded? | D&D Pharmatech was founded in 2014. |
| Where is D&D Pharmatech headquartered? | D&D Pharmatech is headquartered in South Korea. |
| Is D&D Pharmatech publicy listed? | Yes, D&D Pharmatech is a public company listed on KRX. |
| What is the stock symbol of D&D Pharmatech? | D&D Pharmatech trades under 347850 ticker. |
| When did D&D Pharmatech go public? | D&D Pharmatech went public in 2024. |
| Who are competitors of D&D Pharmatech? | Similar companies to D&D Pharmatech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of D&D Pharmatech? | D&D Pharmatech's current market cap is $673M |
| Is D&D Pharmatech profitable? | Yes, D&D Pharmatech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
